BROKENSHIRE COLLEGE

Madapo, Davao City

DRUG STUDY
Name of Client:_____________________________ Age:___ Sex:______ Date of Birth:__________ Marital Status:___________ Religion:____________
Chief Complaint/Reason for Admission:___________________________________________________________________________________________
Date and Time of Admission:_________________________________________ Accompanied by/Informant:___________________________________
Medical Diagnosis/Impression:________________________________________ Operation Perform (if any):____________________________________
GENERIC BRAND GENERAL MECHANISM ROUTE OF ADVERSE NURSING
INDICATIONS CONTRAINDICATIONS
NAME NAME CLASSIFICATION OF ACTION DOSAGE REACTIONS RESPONSIBILITY
Bevacizumab Avastin  monoclonal A recombinant Intravenous  Avastin, in  Low levels of female  Dry  Monitor for S&S
antibody humanized  100 mg/4 combination hormones in the mouth, of an infusion
 anti- vascular mL, single with body called  Cough, reaction
angiogenesis endothelial use vial intravenous hypogonadism  Voice (hypersensitivit
growth factor  400 mg/16 fluorouracil-  Decrease of changes, y); infusion
inhibitor. mL, single based neutrophils in the  Loss of should be
use vial chemotherap blood from cancer appetite, interrupted in
y, is chemotherapy  Diarrhea, all patients with
indicated for  Low levels of a type  Nausea, severe infusion
the first-or of white blood cell  Vomiting, reactions and
second-line called neutrophils  Constipati appropriate
treatment of  High blood pressure on, therapy
patients with  A heart attack  Mouth instituted.
metastatic  Angina sores,  Monitor BP at
colorectal  A type of chest pain  Headache, least every 2–3
cancer  Chronic heart failure  Back pain, wk; if
(mCRC).  A hemorrhage in the  Cold hypertension
 Avastin, in brain symptoms develops,
combination  A transient ischemic (stuffy monitor more
with attack nose, frequently,
fluoropyrimi  A type of stroke that sneezing, even after
dine- lasts only a few sore discontinuation
irinotecan-or minutes throat), of bevacizumab.
fluoropyrimi  Obstruction of a  Dry or  Withhold drug
dine- blood vessel by a watery and promptly
oxaliplatin-
 based blood clot eyes, notify physician
chemotherap  Inflammation of the  Dry or for S&S of CHF,
y, is esophagus with flaky skin, hemorrhage
indicated for erosion  Hair loss, (e.g., epistaxis,
the second-  An abnormal  Changes in hemoptysis, or
line connection between your sense GI bleeding), or
treatment of the esophagus and of taste, unexplained
patients with windpipe  Jaw abdominal pain.
mCRC who  A gastrointestinal pain/swelli  Lab tests:
have tract fistula ng/numbn Urinalysis for
progressed  Bleeding of the ess, proteinuria and
on a first-line stomach or  Loose 24 h urine if
Avastinconta intestines teeth, or protein 2+ or
ining  Nephrotic syndrome  Gum greater.
regimen.  A type of kidney infection.  Monitor for
disorder dizziness,
 Bleeding not related lightheadedness
to menstrual period , or loss of
 Recent operation balance. Take
 Elevation of proteins appropriate
in the urine safety
 Impaired wound measures.
healing

Submitted by:____________________________________________________________________Clinical Instructor:_____________________________